NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
SIGA Technologies Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
SIGA Technologies is a pharmaceutical company that sells TPOXX®, an antiviral drug for treating smallpox. The company provides oral and intravenous formulations to the U.S. Government through the Strategic National Stockpile and to international governments, either directly or through distributors. TPOXX® has received regulatory approvals from the FDA, European Medicines Agency, and other authorities.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the SIGA Technologies Inc stock.
Slightly overvalued: intrinsic value $2.51 per share, market price $2.73, margin of safety -8.7% (as of 2026-11-17).
Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $2.51; the price of $2.73 is 9% above that value, and 70% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
10 more in this industry show a wider margin of safety.
SIGA is slightly overvalued (as of the 2026-11-17 close). Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $2.51; the price of $2.73 is 9% above that value, and 70% of that value comes from beyond year five.
$2.51 per share (as of the 2026-11-17 close), against a market price of $2.73. That is a margin of safety of -8.7%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.